Alteration of Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Breast Cancer after Neoadjuvant Chemotherapy.
10.4048/jbc.2007.10.3.206
- Author:
Jong Won LEE
1
;
Wonshik HAN
;
Eunyoung KO
;
Jihyoung CHO
;
So Youn JUNG
;
Eun Kyu KIM
;
Bhumsuk KEAM
;
Seock Ah IM
;
Ho chang LEE
;
In Ae PARK
;
Seung Keun OH
;
Yeo Kyu YOUN
;
Sung Won KIM
;
Ki Tae HWANG
;
Dong Young NOH
Author Information
1. Department of Surgery, Seoul National University College of Medicine, Seoul, Korea. dynoh@plaza.snu.ac.kr
- Publication Type:Original Article
- Keywords:
Breast cancer;
Neoadjuvant chemotherapy;
Tumor marker expression;
Steroid hormone receptor;
HER-2
- MeSH:
Biopsy;
Breast Neoplasms*;
Breast*;
Drug Therapy*;
Estrogens*;
Humans;
Receptors, Progesterone*;
Retrospective Studies
- From:Journal of Breast Cancer
2007;10(3):206-210
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We aimed to assess the concordance of the immunohistochemical profiles of core biopsy before administrating neoadjuvant chemotherapy with that of the surgical specimens after a definitive operation for breast cancer. METHODS: We retrospectively reviewed the estrogen receptor (ER), progesterone receptor (PR), and HER-2 expressions in 130 consecutive patients who received neoadjuvant chemotherapy and were followed by surgery during the period between February 2002 and March 2006. The pathologic complete tumor response rate for this group was 4.6% (6/130). Both the pre- and post-operative immunohistochemical profiles were available in 32 of the 124 patients (25.8%). Immunohistochemical staining was done on the core biopsies before chemotherapy and on the surgical specimens after operation. RESULTS: There were 12 markers from 11 patients that were altered out of the 96 total markers (ER, PR, or HER-2) from 32 patients: 2 ER (2/12, 16.7%), 4 PR (4/12, 33.3%), and 6 HER-2 (6/12, 50.0%). One patient simultaneously had changes in the expressions of PR and HER-2. Conversion of the hormone receptor status occurred in 3 patients (3/32, 9.4%): this was positive to negative in two, and vice versa in one. In addition, there were 6 conversions (6/32, 18.8%) of the HER-2 status from negative to positive. CONCLUSION: The hormone receptor status changed in 9.4% of the 32 patients and the HER-2 status changed in 18.8% of the 32 patients after neoadjuvant chemotherapy. We have concluded that conducting only a single immunohistochemical study about ER, PR, and HER-2 may not be enough to exactly estimate the tumor marker status in the neoadjuvant setting.
